PresentationToday, we are joined by Nick Colangelo, who is the President and CEO at Vericel, who will be leading the presentation and the Q&A. For the Q&A, we have the last few minutes reserve. So please save your questions for the end. Thank you.Good morning, everyone. I'm Dishayu Kapadia. I'm an associate with the Healthcare Investment Banking Group at JPMorgan Chase. Thank you for joining us for the company presentation for Vericel Corp. at the 44th Annual JPMorgan Healthcare Conference in San Francisco. ...

Core Insights - Ernexa Therapeutics is on track to initiate its first-in-human trial for ovarian cancer treatment in the second half of 2026 following a successful Pre-IND meeting with the FDA, which provided strong regulatory alignment and a clear pathway for IND submission [1][3] Group 1: Company Developments - The company has accelerated key operational activities post-FDA meeting, with tech transfer already underway to prepare for clinical manufacturing and trial readiness [2] - Ernexa is advancing two synthetic, allogeneic induced mesenchymal stem cell (iMSC) therapies: ERNA-101 for ovarian cancer and ERNA-201 for autoimmune disease, utilizing reprogrammed induced pluripotent stem cells (iPSCs) [3][5] - The initial clinical development will focus on ERNA-101, targeting ovarian cancer, which currently has limited effective therapies and high recurrence rates [4][6] Group 2: Technology and Approach - Ernexa's engineered iMSCs are designed to target tumors or inflamed tissues, delivering therapeutic cytokines directly to the disease site, which aims to overcome limitations of traditional MSC therapies while enabling scalable manufacturing [3][5] - The company's approach provides an off-the-shelf treatment option without the need for patient-specific cell harvesting, enhancing patient accessibility [5][6]

Group 1 - Nkarta, Inc. is participating in the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 8:30 a.m. ET, featuring a fireside chat [1] - A simultaneous webcast of the event will be available on Nkarta's website, with a replay archived for approximately 90 days [1] - Nkarta is a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases [2] Group 2 - The company utilizes a cell expansion and cryopreservation platform combined with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities [2] - Nkarta aims to build a pipeline of future cell therapies designed for deep therapeutic activity and broad access in outpatient treatment settings [2]

Core Insights - Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases [3] - The company will present and host institutional investor meetings at the Stifel 2025 Healthcare Conference from November 11-13, 2025 [1][2] - The lead candidate, NXC-201, is a BCMA-targeted CAR-T cell therapy currently being evaluated in a U.S. multi-center study for relapsed/refractory AL Amyloidosis [3] Company Overview - Immix Biopharma, Inc. is listed on Nasdaq under the ticker IMMX [3] - NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA and Orphan Drug Designation (ODD) from both the FDA and EMA [3] - Interim results for NXC-201 were presented at ASCO 2025, indicating ongoing clinical evaluation [3] Investor Engagement - The company will be available for one-on-one meetings during the Stifel conference, encouraging interested investors to contact their Stifel representative [2] - A replay of the presentation will be accessible on the Immix website under the Investors section [2]

Group 1 - Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies [1][3] - The company is participating in the H.C. Wainwright "HCW@Home" Series, with a fireside chat scheduled for July 30, 2025 [2] - Nkarta is advancing allogeneic, off-the-shelf NK cell therapies aimed at treating autoimmune diseases, utilizing a combination of cell expansion, cryopreservation, and CRISPR-based genome engineering [3] Group 2 - The event will be available via a simultaneous webcast on Nkarta's website, with a replay accessible for approximately 90 days [2] - Nkarta's approach is designed for deep therapeutic activity and broad access in outpatient treatment settings [3] - For further information, Nkarta's media and investor contact is Nadir Mahmood [4]

Group 1 - Mustang Bio, Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement as per Nasdaq Listing Rule 5550(b)(1) [1][2] - The company previously satisfied the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing, thus meeting all Nasdaq Capital Market listing requirements [2] - Mustang Bio is a clinical-stage biopharmaceutical company focused on developing cell therapies for difficult-to-treat cancers, aiming to license or acquire technologies to fund research and development [3] Group 2 - Mustang Bio has partnered with leading medical institutions to advance CAR-T therapies [3] - The company's common stock is registered under the Securities Exchange Act of 1934 and it files periodic reports with the SEC [3]

Core Viewpoint - Mustang Bio, Inc. has exited its lease for a manufacturing facility in Worcester, Massachusetts, and divested certain fixed assets to AbbVie for $1.0 million, while relocating its corporate headquarters to Waltham, Massachusetts [1][2]. Group 1: Financial Implications - The termination of the lease is expected to result in approximately $2.0 million in cash expense savings over the next 24 months [2]. - The divestment of fixed assets to AbbVie Bioresearch Center Inc. was completed for a total of $1.0 million [1]. Group 2: Strategic Focus - The company remains committed to advancing its existing portfolio and plans to initiate a novel clinical trial with MB-109, targeting recurrent glioblastoma and high-grade astrocytomas in the second half of 2025 [3]. - MB-109 is a combination therapy that includes MB-101 (IL13Rα2-targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), aimed at enhancing the efficacy of CAR-T cell therapy by modifying the tumor microenvironment [4]. Group 3: Company Overview - Mustang Bio is a clinical-stage biopharmaceutical company focused on developing cell therapies for difficult-to-treat cancers, partnering with leading medical institutions to advance CAR-T therapies [5].